Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

R&D Returns for Pharma Reached Six-Year Low in 2016

By Ryan Bushey | January 3, 2017

An analysis published by Deloitte’s Centre for Health Solutions indicated the pharmaceutical industry experienced a continued decline in R&D returns for 2016.

The annual report was published in December.  It projected the return on investment for the top 12 drugmakers would be 3.7 percent after hitting a high of 10.1 percent in 2010 when the company started compiling these reports.

Furthermore, midtier biotech companies saw their returns on investment go from 17.4 percent in 2013 to 9.9 percent in 2016, according to FierceBiotech.

Deloitte’s report suggests some factors for these declines include a rise in development costs and increasing political pressure over drug pricing for important medicine.

“The majority of companies are struggling to achieve historical peak sales,” explained Colin Terry, a director in Deloitte’s life sciences practice an co-author of the report, to Reuters.

“As costs per product remain high, sales projections decline, and given it now takes the industry over 14 years to launch a drug, real questions should be raised about productivity and returns on innovation,” continued Terry.

The firm’s assessment has a few recommendations for pharma companies to consider as they prepare for new R&D initiatives. 

Drug companies could adopt a “think small, win big” strategy when it comes to development options like having a narrow focus on specific disease areas that potentially could yield higher peak sales, simplify the use of data throughout the clinical trial process, and streamline decision-making throughout the organization in order to increase commercial success.

Also, one method for dealing with the drug-pricing dilemma could be self- regulation. Allergan and Novo Nordisk are two specific firms who pledged to limit price hikes to a specific percentage for certain drugs each year.

Ultimately, Deloitte predicts an uptick in mergers and acquisitions activity this year to compensate for these low returns.

“With late-stage pipelines of the largest companies at their lowest values since we began conducting the study, and peak sales/assets also at its lowest point, we expect to see an increase in the amount of external innovation and M&A activity in the coming year as Big Pharma looks to replenish pipelines,” explained Deloitte’s Neil Lesser, U.S. principal and life science R&D strategy lead, in an email to MedCity News.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE